Correspondence 0001493152-23-020974 from OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)
OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: June 12, 2023 · CIK: 0001849296 · Accession: 0001493152-23-020974
AI Filing Summary & Sentiment
File numbers found in text: 333-272005
Letter
OKYO Pharma Limited
Martello Court
Admiral Park
St. Peter Port
Guernsey GY1 3HB
June 12, 2023
VIA EDGAR
United States Securities and Exchange Commission
F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re: OKYO Pharma Limited
Registration Statement on Form F-1/A
June 9, 2023
File No. 333-272005
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, OKYO Pharma Limited (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Wednesday, June 14, 2023, or as soon thereafter as possible.
Please notify Jeff Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
OKYO Pharma Limited
By: /s/ Gary Jacob
Name: Gary Jacob
Title: Chief Executive Officer
-1-
Show Raw Text
CORRESP
1
filename1.htm
OKYO
Pharma Limited
Martello
Court
Admiral
Park
St.
Peter Port
Guernsey
GY1 3HB
June
12, 2023
VIA
EDGAR
United
States Securities and Exchange Commission
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Daniel Crawford
Re:
OKYO
Pharma Limited
Registration
Statement on Form F-1/A
June
9, 2023
File
No. 333-272005
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, OKYO Pharma Limited (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective
at 4:00 p.m., Eastern Daylight Time, on Wednesday, June 14, 2023, or as soon thereafter as possible.
Please
notify Jeff Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as
to the time the Registration Statement has been declared effective pursuant to this acceleration request.
OKYO
Pharma Limited
By:
/s/
Gary Jacob
Name:
Gary
Jacob
Title:
Chief Executive
Officer
-1-